\documentclass[12pt]{article}
\usepackage{amsmath, amssymb,amsthm, epsfig,epstopdf}
%\setlength{\topsep}{4mm} \setlength{\topmargin}{-0.3in}
\setlength{\headheight}{-0.5 in} \setlength{\textwidth}{6.8in}
\setlength{\textheight}{9in} \setlength{\oddsidemargin}{-0.2in}
\setlength{\footskip}{0.5in}
\newcommand{\br}{{\mathbf{r}}}
\newcommand{\bs}{{\mathbf{s}}}
\newcommand{\betahat}{{\widehat{\beta}}}
\newcommand{\gammatilde}{{\widetilde{\gamma}}}


\begin{document}

\begin{center}
{\large \bf Supplementary material to exact and efficient inference procedure for meta analysis and 
its application to the analysis of independent $2 \times 2$ tables with all available data but without 
artificial continuity correction}


\vspace{0.1 in}

Lu Tian$^1$, Tianxi Cai$^2$, Marc A. Pfeffer$^3,$ \\ Nikita
Piankov$^4$, Pierre-Yves Cremieux$^{4,5}$ and L. J. Wei$^2$ \\
\vspace{.1in}

\noindent
{\it \footnotemark[1] Department of Preventive Medicine, Northwestern University, Chicago IL\\
\footnotemark[2] Department of Biostatistics, Harvard University, Boston, MA \\
\footnotemark[3] Cardiovascular Division, Brigham \& Women's Hospital\\
\footnotemark[4] Analysis Group, Boston MA \\
\footnotemark[5] Department of Economics, University of Quebec at
Montreal, Montreal, Quebec, Canada}
\\

\end{center}

\newpage
\begin{table}
\begin{center}
Table I. Number of Patients,  Myocardial Infarctions (MI), and
Cardiovascular death (Death) for 48 Rosiglitazone comparative
studies. {\footnotesize
\begin{tabular}{ccccccccc}
\hline \\
ID & {\bf Study} & \multicolumn{3}{c}{{\bf Rosiglitazone Group}}& & \multicolumn{3}{c}{{\bf Control Group}} \\
   &   & Patient   &  MI   & Death && Patient  & MI  & Death \\
1 & 49653/011& 357 & 2 & 1 && 176 & 0 & 0\\
2 & 49653/020& 391 & 2 & 0 && 207 & 1 & 0\\
3 & 49653/024& 774 & 1 & 0 && 185 & 1 & 0\\
4 & 49653/093& 213 & 0 & 0 && 109 & 1 & 0\\
5 & 49653/094& 232 & 1 & 1 && 116 & 0 & 0\\
6 & 100684   & ~43 & 0 & 0 && ~47 & 1 & 0\\
7 & 49653/143& 121 & 1 & 0 && 124 & 0 & 0\\
8 & 49653/211& 110 & 5 & 3 && 114 & 2 & 2\\
9 & 49653/284& 382 & 1 & 0 && 384 & 0 & 0\\
10& 712753/008&284 & 1 & 0 && 135 & 0 & 0\\
11& AVM100264& 294 & 0 & 2 && 302 & 1 & 1\\
12& BRL49653C/185 & 563 & 2 & 0 && 142 & 0 & 0\\
13& BRL49653/334  & 278 & 2 & 0 && 279 & 1 & 1\\
14& BRL49653/347  & 418 & 2 & 0 && 212 & 0 & 0\\
15& 49653/015  & 395 & 2 & 2 && 198 & 1 & 0\\
16& 49653/079  & 203 & 1 & 1 && 106 & 1 & 1\\
17& 49653/080  & 104 & 1 & 0 && ~99 & 2 & 0\\
18& 49653/082  & 212 & 2 & 1 && 107 & 0 & 0\\
19& 49653/085  & 138 & 3 & 1 && 139 & 1 & 0\\
20& 49653/095  & 196 & 0 & 1 && ~96 & 0 & 0\\
21& 49653/097  & 122 & 0 & 0 && 120 & 1 & 0\\
22& 49653/125  & 175 & 0 & 0 && 173 & 1 & 0\\
23& 49653/127  & ~56 & 1 & 0 && ~58 & 0 & 0\\
24& 49653/128  & ~39 & 1 & 0 && ~38 & 0 & 0\\
25& 49653/134  & 561 & 0 & 1 && 276 & 2 & 0\\
26& 49653/135  & 116 & 2 & 2 && 111 & 3 & 1\\
27& 49653/136  & 148 & 1 & 2 && 143 & 0 & 0\\
28& 49653/145  & 231 & 1 & 1 && 242 & 0 & 0\\
29& 49653/147  & ~89 & 1 & 0 && ~88 & 0 & 0\\
30& 49653/162  & 168 & 1 & 1 && 172 & 0 & 0\\
31& 49653/234  & 116 & 0 & 0 && ~61 & 0 & 0\\
32& 49653/330  &1172 & 1 & 1 && 377 & 0 & 0\\
33& 49653/331  & 706 & 0 & 1 && 325 & 0 & 0\\
34& 49653/137  & 204 & 1 & 0 && 185 & 2 & 1\\
35& SB-712753/002& 288 & 1 & 1 && 280 & 0 & 0\\
36& SB-712753/003& 254 & 1 & 0 && 272 & 0 & 0\\
37& SB-712753/007& 314 & 1 & 0 && 154 & 0 & 0\\
38& SB-712753/009& 162 & 0 & 0 && 160 & 0 & 0\\
39& 49653/132  & 442 & 1 & 1 && 112 & 0 & 0\\
40& AVA100193  & 394 & 1 & 1 && 124 & 0 & 0\\
41& DREAM      &2635 & 15& 12&&2634 & 9 & 10\\
42& ADOPT      &1456 & 27& 2 &&2895 & 41& 5\\
43& 49653/044$^*$  & 101 & 0 & 0 && ~51 & 0 & 0\\
44& 49653/096$^*$ & 232 & 0 & 0 && 115 & 0 & 0\\
45& 49653/282$^*$ & ~70 & 0 & 0 && ~75 & 0 & 0\\
46& 49653/369$^*$ & ~25 & 0 & 0 && ~24 & 0 & 0\\
47& 49653/325$^*$  & 196 & 0 & 0 && 195 & 0 & 0\\
48& 797620/004$^*$& 676 & 0 & 0 && 225 & 0 & 0\\
\hline \\
\multicolumn{9}{l}{$^*:$ Not reported in Table 1 of Nissen and
Wolski (2007)}
\end{tabular}
}
\end{center}

\end{table}
\clearpage


\newpage
\begin{figure}
\begin{center}
{\bf FIGURE I.} 95\% confidence intervals of the log(odds ratio) for
MI and CVD death (control is the reference group) with 48 studies
listed in Table 1 (Small circles are the observed log(odds ratios)
\end{center}
\includegraphics[height=6 in]{or.eps}
\end{figure}
\label{or} \clearpage


\newpage
\begin{figure}
\begin{center}
{\bf FIGURE II.} 95\% confidence intervals of the risk difference for
MI (Rosiglitazone minus control) with 48 studies listed in Table 1
(Small circles are the observed risk differences)
\end{center}
\includegraphics[ height=6 in]{finalMI.eps}
\end{figure}
\label{rdMI}




\end{document}